Evaluation of Pharmacogenetic Testing In a Mental Health Population and Economic Outcomes
NCT02474680 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 84
Last updated 2017-05-03
Summary
This is a non-randomized, single-case design of pharmacogenetic implementation in a mental health patient population of subjects taking antipsychotics and/or antidepressants.
Conditions
- Major Depressive Disorder 1
Interventions
- GENETIC
-
Pharmacogenetic testing
Psychotropic genotyping panel
Sponsors & Collaborators
-
Avera McKennan Hospital & University Health Center
lead OTHER
Principal Investigators
-
Matthew Stanely, MD · Avera McKennan Hospital & University Health Center
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-11-01
- Primary Completion
- 2017-01-01
- Completion
- 2017-01-01
Countries
- United States
Study Locations
More Related Trials
-
Pharmacogenetic-Directed Treatment for Major Depression
NCT01261364 ·Status: COMPLETED ·Phase: NA
-
Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment of Major Depressive Disorder
NCT02466477 ·Status: COMPLETED ·Phase: PHASE4
-
McLean and Genomind Prospective Study
NCT03113890 ·Status: COMPLETED ·Phase: NA
-
Clinical Study Evaluating Effects of Pharmacogenetic-guided vs Standard-of-Care Treatment on Depression and/or Anxiety
NCT02878928 ·Status: COMPLETED ·Phase: NA
-
Pharmacogenetic Decision Support IT System for Psychiatric Hospitalization: RCT
NCT02120729 ·Status: UNKNOWN ·Phase: NA
-
Pharmacogenomics for Antidepressant Guidance and Education
NCT01555021 ·Status: TERMINATED
-
Genomics Used to Improve DEpression Decisions
NCT02109939 ·Status: COMPLETED ·Phase: NA
-
Pharmacogenomics for Antidepressant Guidance and Education 1 (PAGE-1_AG1)
NCT01426516 ·Status: TERMINATED ·Phase: NA
-
Retrospective Analysis of Outcomes With a Pharmacogenomic Algorithm
NCT01632267 ·Status: COMPLETED
-
Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression
NCT04469322 ·Status: COMPLETED ·Phase: NA
-
Pharmacogenetic-Guided Antidepressant Prescribing in Adolescents With Anxiety and Depression
NCT06853587 ·Status: RECRUITING ·Phase: NA
-
Outcome Following Antidepressant Treatment on Possible Endo-Phenotypes for Major Depression
NCT00386841 ·Status: COMPLETED ·Phase: PHASE4
-
Pharmacist Guided Pre-emptive Pharmacogenetic Testing in Antidepressant Therapy
NCT04507555 ·Status: RECRUITING ·Phase: NA
-
PRIME Care (PRecision Medicine In MEntal Health Care)
NCT03170362 ·Status: COMPLETED ·Phase: NA
-
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)
NCT00035048 ·Status: COMPLETED ·Phase: PHASE3
-
Long-term Follow-up of Depressive Disorders in Psychiatric Care
NCT07078227 ·Status: RECRUITING
-
Trial to Evaluate Efficacy of Pharmacogenetic Information Obtained With NEUROPHARMAGEN in Treatment of MDD Patients
NCT02529462 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacogenetic Study of Mirtazapine Response in Depressed Patients
NCT01039740 ·Status: UNKNOWN ·Phase: NA
-
Confirm the Effectiveness of Predictix Genetics Antidepressant -Guided Treatment in Adults With MDD
NCT05137197 ·Status: UNKNOWN ·Phase: NA
-
Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder
NCT05952713 ·Status: COMPLETED
-
Pharmacogenetics Anomaly Research in Children and Adolescents With Pharmacological Resistance to Psychotropic Drugs
NCT03114098 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)
NCT03864614 ·Status: COMPLETED ·Phase: PHASE3
-
Genecept Assay™ vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults With MDD
NCT02634177 ·Status: COMPLETED ·Phase: NA
-
Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)
NCT00048594 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacogenetic-Guided Antidepressant Prescribing in Adolescents
NCT05965401 ·Status: TERMINATED ·Phase: NA